[go: up one dir, main page]

PE20040362A1 - Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa - Google Patents

Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa

Info

Publication number
PE20040362A1
PE20040362A1 PE2003000438A PE2003000438A PE20040362A1 PE 20040362 A1 PE20040362 A1 PE 20040362A1 PE 2003000438 A PE2003000438 A PE 2003000438A PE 2003000438 A PE2003000438 A PE 2003000438A PE 20040362 A1 PE20040362 A1 PE 20040362A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
oxopiperidin
oxo
fluoro
Prior art date
Application number
PE2003000438A
Other languages
English (en)
Inventor
Wei Han
Zilun Hu
Shuaige Wang
Jennifer X Quiao
Joanne M Smallheer
Donald J Pinto
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040362A1 publication Critical patent/PE20040362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE SULFONILAMINOVALEROLACTAMAS DE FORMULA Ia, Ib O Ic O UN ESTEREOISOMERO, DONDE EL ANILLO LACTAMA CENTRAL POSEE UN G, G1, A Y B; DONDE G ES UN HETEROCICLICO MONO O BICICLICO; G1 PUEDE SER H, (CR3R3a)C1-C2(O)R2, (CR3R3a)O1-O2R2, ENTRE OTROS; A ES CARBOCICLO C3-C10 SUSTITUIDO, HETEROCICLO C5-C12, ENTRE OTROS; Y B ES X-Y-R4a, ENTRE OTROS; X ESTA AUSENTE O ES -C(O)-, CR2(OR2)-, O, ENTRE OTROS; Y ES CARBOCICLO C3-C10, HETEROCICLO C3-C10, ENTRE OTROS; R2 ES H, CF3, ALQUILO C1-C6, ENTRE OTROS; R3 Y R3a SON H, CH3, CH2CH3, BENCILO, FENILO, ENTRE OTROS; R4a ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {1-[2-FLUORO-4-(2-OXO-PIPERIDIN-1-IL)-FENIL]-2-OXOPIPERIDIN-3-IL}-AMIDA DEL ACIDO 6-CLORONAFTALEN-2-SULFONICO, {1-[2-FLUORO-4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-2-OXOPIPERIDIN-3-IL}-AMIDA DEL ACIDO 6-CLORONAFTALEN-2-SULFONICO, {1-[2-FLUORO-4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-2-OXOPIPERIDIN-3-IL}-AMIDA DEL ACIDO 6-CLOROTIENO[2,3-b]PIRIDINA-2-SULFONICO, ENTRE OTROS; DICHOS COMPUESTOS SON INHIBIDORES DE LA SERINA PROTEASA TIPO TRIPSINA ESPECIFICAMENTE DEL FACTOR Xa Y SON UTILES EN EL TRATAMIENTO DE PADECIMIENTOS TROMBOEMBOLICOS
PE2003000438A 2002-05-06 2003-05-06 Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa PE20040362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37831302P 2002-05-06 2002-05-06

Publications (1)

Publication Number Publication Date
PE20040362A1 true PE20040362A1 (es) 2004-06-17

Family

ID=32312390

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000438A PE20040362A1 (es) 2002-05-06 2003-05-06 Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa

Country Status (7)

Country Link
US (2) US7157470B2 (es)
EP (1) EP1501798A4 (es)
AR (1) AR040410A1 (es)
AU (1) AU2003301863A1 (es)
PE (1) PE20040362A1 (es)
TW (1) TW200307667A (es)
WO (1) WO2004041776A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187023A1 (en) * 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
AU2003284596A1 (en) * 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
GB0314299D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
US20050070531A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7163937B2 (en) * 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GEP20094679B (en) * 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
TWI335816B (en) * 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
GB0419744D0 (en) * 2004-09-06 2004-10-06 Glaxo Group Ltd Chemical compounds
DE602005019602D1 (de) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
EP1830841B1 (en) * 2004-12-20 2008-07-02 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006068991A1 (en) * 2004-12-21 2006-06-29 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1828192B1 (en) * 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006108709A1 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors
US20070060530A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
EA015735B1 (ru) * 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) * 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
JPWO2007058304A1 (ja) * 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
EP1950211A4 (en) * 2005-11-18 2011-08-31 Eisai R&D Man Co Ltd PROCESS FOR PREPARING A CINEMA ACID AMID DERIVATIVE
TW200738694A (en) * 2005-11-24 2007-10-16 Glaxo Group Ltd Chemical compounds
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2652484A1 (en) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Heterocyclic type cinnamide derivative
US20100105904A1 (en) * 2006-05-19 2010-04-29 Teiji Kimura Urea type cinnamide derivative
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0712823A2 (pt) * 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
US7671062B2 (en) * 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008140111A1 (ja) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. シンナミド誘導体のワンポット製造方法
JP5433418B2 (ja) 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
GB2455539B (en) * 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
AU2013216616B2 (en) * 2007-12-14 2016-04-21 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives
EP2239265A1 (en) * 2008-01-28 2010-10-13 Eisai R&D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
EP2445879A1 (en) 2009-06-25 2012-05-02 Institut Univ. de Ciència i Tecnologia, S.A. N-(2-oxo-1-phenylpiperidin-3-yl) sulfonamides for the identification of biological and pharmacological activity
ES2354550B1 (es) * 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. Biblioteca de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para el descubrimiento de fármacos.
ES2354551B1 (es) * 2009-07-01 2011-11-15 Institut Univ. De Ciencia I Tecnologia S.A. Bibliotecas de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para la identificación de actividad biológica y farmacológica.
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
EP2875001B1 (en) * 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP3587416A1 (en) 2018-06-29 2020-01-01 Institut Univ. de Ciència i Tecnologia, S.A. 2-oxopiperidin-3-yl derivatives and use thereof
EP3586847A1 (en) * 2018-06-29 2020-01-01 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Compounds for use in preventing or treating cancer
EP4356909A1 (en) 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032602A (en) * 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
EP0454444A1 (en) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimide derivatives and herbicides
ATE152102T1 (de) 1991-05-10 1997-05-15 Takeda Chemical Industries Ltd Pyridinderivate, deren herstellung und anwendung
DE69433705T2 (de) 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
CA2250353A1 (en) 1996-04-03 1997-10-09 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE69804402D1 (de) 1997-10-06 2002-05-02 Agfa Gevaert Nv Verfahren zur Verarbeitung eines photographischen Schwarzweiss-Silberhalogenidmaterials
WO1999031506A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Parallel solution phase synthesis of lactams
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
CN1143855C (zh) 1997-12-19 2004-03-31 舍林公开股份有限公司 作为抗凝剂的邻氨基苯甲酰胺衍生物
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
EP1178971A1 (en) 1999-05-19 2002-02-13 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
JP2002544260A (ja) 1999-05-19 2002-12-24 ファルマシア・コーポレイション 凝固カスケードの選択的阻害剤として有用な置換された多環式アリールまたはヘテロアリールピリドン
NZ514874A (en) 1999-05-19 2004-11-26 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
PL352368A1 (en) 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Also Published As

Publication number Publication date
US7157470B2 (en) 2007-01-02
EP1501798A4 (en) 2006-11-22
US20060247243A1 (en) 2006-11-02
US7524863B2 (en) 2009-04-28
EP1501798A2 (en) 2005-02-02
WO2004041776A3 (en) 2004-09-10
WO2004041776A2 (en) 2004-05-21
TW200307667A (en) 2003-12-16
AR040410A1 (es) 2005-04-06
AU2003301863A8 (en) 2004-06-07
US20040006062A1 (en) 2004-01-08
AU2003301863A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
PE20040362A1 (es) Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa
PE20091738A1 (es) Inhibidores de quinasa de pirrolopirazina
PE20121806A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
UY31507A1 (es) Derivados de piridina activadores de guanilato ciclasa soluble
AR038382A1 (es) Compuesto inhibidor de la hepatitis c
AR038383A1 (es) Compuesto inhibidor de la hepatitis c
PE20030199A1 (es) Derivados de n-[benzoil]-fenilsulfonamida
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
CO5690642A2 (es) Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
TN2010000173A1 (fr) Antagonistes de cgrp
PE20040844A1 (es) Acidos fenilaceticos y derivados como inhibidores de la cox-2
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
DK1513526T3 (da) Phenylalkansyre- og phenyloxyalkansyrederivater som hPPAR-aktivatorer
NO20080739L (no) Fremgangsmater for behandling av Epileptogenese
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
WO2007048847A3 (en) Indole and azaindole derivatives for the treatment of inflammatory and autoimmune diseases
DOP2001000242A (es) Derivados de fenoxibencilamina como ssri
PE20060585A1 (es) Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
PE20071132A1 (es) Compuestos macrociclicos como inhibidores del factor viia

Legal Events

Date Code Title Description
FC Refusal